Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta.
<h4>Background</h4>A relatively large proportion of relapsing-remitting multiple sclerosis (RRMS) patients do not respond to interferon-beta (IFNb) treatment. In previous studies with peripheral blood mononuclear cells (PBMC), we identified a subgroup of IFNb non-responders that was char...
Main Authors: | Marta F Bustamante, Ramil N Nurtdinov, Jordi Río, Xavier Montalban, Manuel Comabella |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23637780/pdf/?tool=EBI |
Similar Items
-
Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.
by: Lisa G M van Baarsen, et al.
Published: (2008-04-01) -
Search for specific biomarkers of IFNβ bioactivity in patients with multiple sclerosis.
by: Sunny Malhotra, et al.
Published: (2011-01-01) -
Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
by: Masoud Mohammad Malekzadeh, et al.
Published: (2020-06-01) -
Beta-interferons in multiple sclerosis
by: Aggarwal Sourabh, et al.
Published: (2010-01-01) -
Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients.
by: Elisabet Matas, et al.
Published: (2014-01-01)